Brief: Senzime YTD May 2023 Sales Have Tripled Compared To Same Period Last Year
June 2 (Reuters) - Senzime AB (publ) SEZI.ST :
* DRIVING FORCES ARE US MARKET AND SUPPORT OF NEW CLINICAL
GUIDELINES
* YTD MAY 2023 SALES HAVE TRIPLED COMPARED TO SAME PERIOD
LAST
YEAR
* NUMBER OF DISPOSABLE SENSORS SOLD IS ESTIMATED TO BE CLOSE
TO
40,000 IN H1- INCREASE FROM ABOUT 15,000 SENSORS SOLD IN H1 OF
202
* SENZIMES GOAL IS TO REACH A MARKET SHARE OF AT LEAST 10
PERCENT
IN ITS ACTIVE MARKET SEGMENTS
Further company coverage: SEZI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Senzime AB (publ)
See all newsBrief: Senzime Tetragraph System Receives Anvisa Approval For Sale In Brazil
Brief: Senzime Secures Contract With U.S. Hospital
Brief: Senzime Gets Additional FDA Class II 510(K) Clearance For Tetragraph System
Brief: Senzime's TetraGraph System Contracted On Three GPO Agreements In U.S.
Sweden's Senzime Q1 sales dip on weak US markets, strong krona